|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Genentech |
| Information provided by: | Genentech |
| ClinicalTrials.gov Identifier: | NCT00096928 |
Purpose
This is a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psoriasis who are candidates for treatment with Raptiva.
| Condition | Phase |
|
Psoriasis |
Phase IV |
| MedlinePlus related topics: | Psoriasis |
| ChemIDplus related topics: | Efalizumab |
| Study Type: | Observational |
| Study Design: | Case Control, Prospective |
| Official Title: | Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) |
| Estimated Enrollment: | 5500 |
| Study Start Date: | March 2005 |
| Groups/Cohorts |
|
1
Raptiva-treated patients
|
|
2
Non Raptiva-treated patients
|
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
managed care organizations, community or physician practices, and academic centers in the United States
Inclusion Criteria:
Exclusion Criterion:
Notes:
If you are a doctor who is interested in participating as a study site, contact the RESPONSE Registry hotline for more information.
If you are an interested patient, contact your dermatologist (or the doctor treating your psoriasis) regarding this study. A list of participating doctors is below. If your doctor is not listed, then he/she can call the RESPONSE Registry Hotline at 1-800-516-1505 for more information.
Contacts and Locations| Contact: RESPONSE Registry Hotline | 800-516-1505 |
![]() |
Show 185 Study Locations |
| Genentech |
| Study Director: | Ivor Caro, M.D. | Genentech |
More Information
| Responsible Party: | Genentech, Inc. ( Clinical Trials Posting Group ) |
| Study ID Numbers: | ACD3101g |
| First Received: | November 17, 2004 |
| Last Updated: | May 21, 2008 |
| ClinicalTrials.gov Identifier: | NCT00096928 |
| Health Authority: | United States: Food and Drug Administration |
|
|